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Summary 
In addition to cholesterol-lowering properties, 
statins exhibit lipid-independent 
immunomodulatory, anti-inflammatory actions. 
However, high concentrations are typically 
required to induce these effects in vitro, raising 
questions concerning therapeutic relevance. We 
present evidence that endothelial cell sensitivity 
to statins depends upon shear stress.  Using heme 
oxygenase-1 expression as a model, we 
demonstrate differential heme oxygenase-1 
induction by atorvastatin in atheroresistant 
compared to atheroprone sites of the murine 
aorta. In vitro, exposure of human endothelial 
cells to laminar shear stress significantly reduced 
the statin concentration required to induce heme 
oxygenase-1 and protect against H2O2-mediated 
injury. Synergy was observed between laminar 
shear stress and atorvastatin, resulting in optimal 
expression of heme oxygenase-1 and resistance 
to oxidative stress, a response inhibited by heme 
oxygenase-1 siRNA. Moreover, treatment of 
LSS-exposed EC resulted in a significant fall in 
intracellular cholesterol. Mechanistically, 
synergy required Akt phosphorylation, activation 
of KLF2, Nrf2, increased nitric oxide synthase 
activity, and enhanced HO-1 mRNA stability. In 
contrast, heme oxygenase-1 induction by 
atorvastatin in endothelial cells exposed to 
oscillatory flow was markedly attenuated. We 
have identified a novel relationship between 
laminar shear stress and statins, demonstrating 
that atorvastatin-mediated heme oxygenase-1-
dependent antioxidant effects are laminar shear 
stress-dependent, proving the principle that 
biomechanical signalling contributes 
significantly to endothelial responsiveness to 
pharmacological agents. Our findings suggest 
statin pleiotropy may be sub-optimal at disturbed 
flow atherosusceptible sites, emphasizing the 
need for more specific therapeutic agents, such 
as those targeting KLF2 or Nrf2. 
 
 
Introduction 
The efficacy of 3-hydroxy-3-methylglutaryl 
coenzyme A reductase antagonists (statins) in 
reducing low-density lipoprotein (LDL)2 
cholesterol, cardiovascular morbidity and 
mortality is widely recognized (1). The 
observation that beneficial actions of statins on 
vascular function are detectable prior to any fall 
in serum cholesterol, extend to 
normocholesterolemic patients and exceed those 
of other lipid-lowering drugs despite comparable 
falls in total cholesterol (2,3), suggest the 
existence of LDL-cholesterol-independent 
effects (4,5). Judging from in vitro studies, these 
may include immunomodulatory, anti-
inflammatory, anti-adhesive, anti-thrombotic and 
cytoprotective actions (6). However, the 
experimental work demonstrating these 
pleiotropic effects has predominantly used statin 
concentrations exceeding those achieved by 
therapeutic dosing, raising questions concerning 
clinical relevance (4).   
 
Heme oxygenase-1 (HO-1) acts as the rate-
limiting factor in the catabolism of heme into 
biliverdin, releasing free Fe and carbon 
monoxide (CO). Biliverdin is subsequently 
converted to bilirubin by biliverdin reductase, 
while intracellular Fe induces expression of 
heavy chain-ferritin and the opening of Fe2+ 
export channels (7). The biologic activity of HO-
1 represents an important adaptive response in 
cellular homeostasis, as revealed by widespread 
inflammation and persistent endothelial injury in 
human HO-1 deficiency (8). 
 
Expression of HO-1 in atherosclerotic lesions, 
and its ability to inhibit vascular smooth muscle 
cell (VSMC) proliferation, exert anti-
inflammatory, anti-oxidant and anti-thrombotic 
effects, suggests a protective role during 
atherogenesis (9,10). HMOX1 promoter 
polymorphisms affecting HO-1 expression may 
influence susceptibility to intimal hyperplasia 
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and coronary artery disease, while a low serum 
bilirubin constitutes a cardiovascular risk factor 
(11). Moreover, over-expression of HO-1 
inhibited atherogenesis, while Hmox1-/- mice 
bred onto an ApoE-/- background developed more 
extensive and complex atherosclerotic plaques 
(12,13). 
 
Recent interest has focused on the therapeutic 
potential of HO-1 and its products, with probucol, 
statins, rapamycin, nitric oxide donors and 
aspirin being shown to induce HO-1 (reviewed in 
(10)). Indeed, induction of HO-1 may represent 
an important component of the vasculoprotective 
profile of statins, with simvastatin, atorvastatin 
and rosuvastatin variously shown to increase 
HMOX1 promoter activity and mRNA levels, to 
induce enzyme activity and increase anti-oxidant 
capacity in human endothelial cells (EC) (14-18). 
However, induction of HO-1 in vascular EC in 
vivo has not yet been demonstrated. 
 
Vascular endothelium exposed to unidirectional, 
pulsatile laminar shear stress (LSS) >10 
dynes/cm2 is relatively protected against 
atherogenesis. LSS increases nitric oxide (NO) 
biosynthesis, prolongs EC survival and generates 
an anticoagulant, anti-adhesive cell surface. In 
contrast, endothelium exposed to disturbed blood 
flow (DF), with low shear reversing or 
oscillatory flow patterns, such as that located at 
arterial branch points and curvatures, is 
atheroprone. Thus endothelial cells exposed to 
DF exhibit reduced levels of endothelial nitric 
oxide synthase (eNOS), increased apoptosis, 
oxidative stress, permeability to LDL and 
leukocyte adhesion (19).  
 
The atheroprotective influence of unidirectional 
LSS and the overlap between these actions and 
those of statins led us to hypothesize that LSS 
increases endothelial responsiveness to statins. 
We demonstrate for the first time that treatment 
of mice with atorvastatin induces HO-1 
expression in the aortic endothelium and that this 
occurs preferentially at sites exposed to LSS. In 
vitro, pre-conditioning human EC with an 
atheroprotective, but not an atheroprone 
waveform, significantly reduces the 
concentration of atorvastatin required to enhance 
HO-1-mediated cytoprotection against oxidant-
induced injury. A synergistic relationship 
between LSS and statins is revealed, resulting in 
maximal Akt phosphorylation and dependence 
upon eNOS, Kruppel-like factor 2 (KLF2) and 
NF-E2-related factor-2 (Nrf2) activation.   
 
Experimental procedures 
Reagents 
Actinomycin D, hydrogen peroxide (H2O2), 
paraformaldeyde, Triton X-100, trypan blue and 
anti-α-tubulin antibody were from Sigma-
Aldrich (Poole, UK). Atorvastatin and 
simvastatin were from Merck Biosciences 
(Nottingham, UK) and 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) 
from Promega (Southampton, UK). NG-nitro-L-
arginine methyl ester (L-NAME) from BIOMOL 
(Plymouth Meeting, PA), leptin from R and D 
Systems (Abingdon,UK), anti-phospho-Akt 
(Ser473) antibody from Cell Signaling, (Beverly, 
MA) and anti-HO-1 antibodies from Cambridge 
Bioscience (Cambridge, UK) and Stressgen 
(Victoria, BC). The nuclear extraction kit NE-
PER Nuclear and Cytoplasmic Extraction 
Reagents were from Thermo Fisher Scientific Inc 
(Rockford, IL). Nrf2 activation in EC nuclear 
extracts was analyzed using an Nrf2 TransAM™ 
assay kit (Active Motif, Carlsbad, CA). 
 
Endothelial cell exposure to shear stress 
Human umbilical vein EC (HUVEC) and human 
aortic EC (HAEC; purchased from Promocell, 
Heidelberg, Germany), were cultured as 
described (20). The use of human EC was 
approved by Hammersmith Hospitals Research 
Ethics Committee (ref no. 06/Q0406/21). 
Confluent EC monolayers (passage 3) on 
fibronectin-coated glass slides were exposed to 
control static conditions, high shear 
unidirectional laminar flow (12 dynes/cm2), or 
oscillatory flow (OF) with directional changes of 
flow at 1Hz (+/- 5 dynes/cm2), for up to 48h 
using a parallel-plate flow chamber (Cytodyne, 
La Jolla, CA, USA) as described previously (21). 
To investigate synergy between LSS and statins, 
EC were exposed to static conditions or 
unidirectional LSS (12 dynes/cm2) for a total of 
24h. After 12h, statin or vehicle control was 
added to the culture medium of static cells or to 
the medium in the flow apparatus via the 
injection port while EC remained under 
conditions of continuous LSS. Cell viability was 
assessed by examination of EC monolayers using 
phase contrast microscopy, cell counting and 
estimation of trypan blue exclusion.  
 
RNAi design and transfection 
Previously validated siRNA sequences targeting 
KLF2, HO-1 or scrambled control siRNA were 
transfected into HUVEC using oligofectamine-
based transfection in EBM2 media as described 
(18). 
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HO-1: 
(Sense:5’UGCUGAGUUCAUGAGGAACUU-
3’)  
(Antisense:5’-
GUUCCUCAUGAACUCAGCAUU-3’),  
(Sense:5’-CAUUGCCAGUGCCACCAAGUU-
3’) 
(Antisense:5’-
CUUGGUGGCACUGGCAAUGUU-3’). 
KLF2:  
(Sense:5’-GCCCUACCACUGCAACUGGUU-
3’) 
(Antisense:5’-
CCAGUUGCAGUGGUAGGGCUU-3’), 
(Sense:5’-GUUUGCGCGCUCAGACGAGUU-
3’)  
(Antisense:5’-
CUCGUCUGAGCGCGCAAACUU-3’).  
EC were cultured for 24h in EBM2 and analysed 
for target gene expression by quantitative RT-
PCR or immunoblotting, which demonstrated up 
to 80% reduction in expression as reported (18). 
The specificity of siRNA targeting was 
confirmed using a second set of sequences. 
Efficacy of siRNA was verified in each 
experiment. 
 
Adenoviral transfection and luciferase reporter 
assay 
The recombinant adenovirus expressing 
dominant-negative (DN) Akt was a gift from Dr 
C Wheeler-Jones (Royal Veterinary College, 
London). The adenovirus expressing DN-Nrf2 
which lacks the transactivation domain (Ad-
Nrf2-DN) was provided by Dr Jeffrey A. 
Johnson, University of Wisconsin, Madison (22). 
Adenoviruses were amplified in HEK-293A cells, 
purified and titred using BD Adeno-X 
Purification and Rapid Titer Kits (BD 
Biosciences). HUVEC were infected by 
incubation with adenovirus in serum free M199 
for 2h at 37˚C. The media was then changed to 
M199/10% FBS and HUVEC incubated 
overnight prior to experimentation. Infection of 
HUVEC with a ß-gal control adenovirus 
demonstrated a transfection efficiency of ≥95%. 
The optimal multiplicity of infection (MOI) for 
the DN-Nrf2 and DN-Akt adenoviruses was 
determined by immunoblotting (not shown). The 
plasmid pHO-1-Luc was a gift from J Alam 
(Alton Ochsner Medical Foundation, New 
Orleans). EC were transfected in triplicate with 
pGL3-basic or pHO-1-Luc using microporation 
technology (Digital Bio, Seoul, Korea) as 
described previously (18).  
 
Analysis of oxidative stress and cellular injury 
HUVEC were loaded with 5μM 5-(and-6)-
chloromethyl-2',7'-dichlorodihydrofluorescein 
diacetate acetyl ester (CM-H2DCFDA) 
(Invitrogen, Paisley, UK) for 30 min at 37°C. 
ECs were incubated in serum-free M199 with 
H2O2 (5μM) for 30 min or leptin 100 ng/ml for 
2h and then washed with ice-cold PBS. 
Intracellular dihydrodichlorofluorescein (H2DCF) 
is oxidized to 2,7-dichlorofluorescein and 
quantified by flow-cytometry. H2O2 (50μM) was 
used to induce cellular injury and this was 
quantified using either: (i) trypan blue exclusion; 
or (ii) a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Cell 
numbers were not significantly altered by any of 
the treatment conditions prior to addition of H2O2. 
 
Quantitative real-time PCR  
Quantitative real-time PCR was performed using 
an iCycler (BioRad, Hercules, CA, USA). β-actin, 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) were used as 
housekeeping genes, with data calculated in 
relation to the β-ACTIN gene and verified with 
GAPDH and HPRT. DNase-1-digested total 
RNA (1 μg) was reverse transcribed using 1 μM 
oligo(dT) and Superscript reverse transcriptase 
(Invitrogen, Paisley, UK). cDNA was amplified 
in a 25 μL reaction containing 5 μL of cDNA 
template, 12.5 μL of iSYBR supermix, 0.5 pM 
sense and antisense gene-specific primers, and 
double distilled H2O. Primer sequences used 
were: KLF2 forward 5’-
CTTTCGCCAGCCCGTGCCGCG-3’; KLF2 
reverse 5’- AAGTCCAGCACGCTGTTGAGG-
3’, HO-1 forward 5’-
CTTCTTCACCTTCCCCAACA-3’, HO-1 
reverse 5’-TTCTATCACCCTCTGCCTGA-3’. 
Nrf2 forward 5'-
AAACCAGTGGATCTGCCAAC-3', Nrf2 
reverse 5'-GACCGGGAATATCAGGAACA-3' 
(23), TM forward: 5'-
TTGTGGAATTGGGAGCTTGG-3', TM reverse 
5'-TCTCATGAACTGGATGGGGTG-3' (24), 
and eNOS forward 5'-
TGGCTTTCCCTTCCAGTTC-3', eNOS reverse 
5'-AGAGGCGTTTTGCTCCTTC-3' (24). 
Cycling parameters were 3 min at 95°C, and 40 
cycles of 95°C for 10 s and 56°C for 45 s. 
 
Immunoblotting 
Immunoblotting was performed as described (25). 
HUVEC were incubated with atorvastatin for up 
to 72 h prior to lysis, sodium dodecylsulfate 
polyacrylamide gel electrophoresis and transfer 
to polyvinylidene difluoride membranes 
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(Millipore Corporation, Bedford, MA). 
Immunoblots were probed with primary Abs 
overnight at 4˚C, followed by appropriate 
secondary reagents for 1h at room temperature and 
developed with a chemiluminescence substrate 
(Amersham Pharmacia Biotech, Little Chalfont, 
UK). To ensure equivalent sample loading, 
protein content was determined using the Bio-
Rad Dc protein assay (Bio-Rad, Hercules, CA) 
and membranes stripped and re-probed with a 
control antibody. Integrated density values were 
obtained with an Alpha Innotech ChemiImager 
5500 (Alpha Innotech, San Leandro, CA). 
 
Cholesterol analysis 
The measurement of intracellular cholesterol 
was carried out using a procedure previously 
described in detail by Wang et al. (26).  
 
Animals 
C57BL/6 mice were from Harlan Olac (Bicester, 
Oxford, UK) and housed under controlled 
climactic conditions in microisolator cages with 
autoclaved bedding. Irradiated food and drinking 
water were readily available. All animals were 
housed and studied according to UK Home 
Office guidelines. Sentinel mice were housed 
alongside test animals and regularly screened for 
a standard panel of murine pathogens. 
 
Confocal microscopy 
En face confocal microscopy was used to assess 
changes in the expression of HO-1 in the murine 
aortic vascular endothelium. C57BL/6 mice (n = 
6) were injected intraperitoneally with 
atorvastatin (5mg/kg) or vehicle alone and 
sacrificed 24h later by CO2 inhalation, followed 
by perfusion fixation with 2% formalin and 
harvesting of aortae. Fixed aortae were treated 
with an HO-1 specific primary antibody 
(Cambridge Biosciences) and an Alexafluor568-
conjugated secondary antibody. Stained vessels 
were mounted prior to visualization of 
endothelial surfaces en face using confocal laser-
scanning microscopy (LSM 510 META; Zeiss, 
Oberkochen, Germany). Changes in the 
expression of HO-1 in murine aortic EC located 
in regions of the lesser curvature exposed to 
disturbed flow and both the greater curvature and 
descending aorta exposed to laminar flow were 
quantified as described (27). EC were identified 
by co-staining with anti-CD31 antibody 
conjugated to the fluorophore FITC (Invitrogen, 
Carlsbad, USA). Nuclei were identified using a 
DNA-binding probe with far-red emission 
(Draq5; Biostatus, Leicester, UK). Isotype-
matched monoclonal antibodies against 
irrelevant antigens were used as experimental 
controls for specific staining. HO-1 protein 
expression was quantified by image analysis of 
fluorescence intensity in 100 cells in at least 3 
distinct sites using Image J software 
(http://rsbweb.nih.gov/nih-image/). EC 
fluorescence was measured above a threshold 
intensity defined by background fluorescence.  
 
Statistics 
Data were grouped according to treatment and 
analyzed using GraphPad Prism software (San 
Diego, CA) and the analysis of variance with 
Bonferroni correction or an unpaired Students t-
test. Data are expressed as the mean of individual 
experiments ± SEM. Differences were 
considered significant at P values of <0.05. 
 
Results 
Atorvastatin induces endothelial HO-1 
expression in murine aortic EC 
To establish whether statins increase endothelial 
HO-1 expression in vivo, C57Bl/6 mice were 
treated with atorvastatin for 24h. Changes in HO-
1 expression were quantified by en face confocal 
microscopy of the aortic endothelium, with 
endothelial cells identified by CD31 staining. As 
shown in Figure 1A, treatment with atorvastatin 
induced a significant increase in HO-1 
expression in murine aortic endothelium at a site 
with low probability (LP) of developing 
atherosclerotic lesions (27). In contrast, although 
HO-1 induction was detectable, EC located in the 
lesser curvature of the aorta, which has a high 
probability (HP) of developing lesions, were 
relatively refractory to atorvastatin treatment 
(Figure 1B). Quantification by image analysis 
confirmed that HO-1 induction at HP sites was 
significantly less than that at LP sites (Figure 1C).  
 
LSS and statins exhibit synergy 
Statins and unidirectional LSS separately induce 
EC HO-1 expression in vitro. An established 
physiologic hemodynamic environment was 
therefore used to explore the influence of LSS on 
statin responsiveness. As expected, treatment of 
HUVEC with either 2.5µM atorvastatin under 
static conditions, or exposure of HUVEC to LSS 
for 24h, significantly increased HO-1 mRNA 
levels (Figure 2A). Pre-conditioning of EC with 
LSS (12 dynes/cm2) for 12h prior to addition of 
atorvastatin and continuation of culture under 
LSS for a further 12h resulted in an additive 
increase in HO-1 mRNA (Figure 2A). Reduction 
of the atorvastatin concentration applied to static-
cultured EC to 0.6µM led to loss of HO-1 
induction. In contrast, a significant increase of 
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HO-1 mRNA was still seen when this 
concentration was applied to EC pre-conditioned 
by LSS, with 0.6µM atorvastatin inducing a 14-
fold increase in HO-1 mRNA (Figure 2B). A 
dose-response study confirmed synergy between 
LSS (12 dynes/cm2) and atorvastatin (1.25 and 
0.6µM), and this was lost with 0.3µM 
atorvastatin (Figure 2C). Moreover, further 
studies using an HMOX1 promoter reporter 
construct confirmed synergy between 
atorvastatin (0.6μM) and LSS, as indicated by 
relative luciferase activity (Figure 2D). 
 
A comparable synergistic response was also seen 
with simvastatin (Supplementary 1A), while 
immunoblotting confirmed enhanced induction 
of HO-1 protein by 0.6µM atorvastatin in LSS-
conditioned EC (Figure 2E). The importance of 
the duration of LSS was revealed by loss of the 
synergistic response when pre-conditioning was 
reduced to 6h (Supplementary 1B-C). 
Subsequent experiments performed with HAEC, 
to represent an endothelial surface affected by 
atherosclerosis, demonstrated that they 
responded similarly to HUVEC with synergy 
observed between LSS and atorvastatin (0.6µM), 
resulting in a 13-fold increase in HO-1 mRNA 
(Supplementary 1D).   
 
Differential regulation of HO-1 in EC exposed to 
LSS and OF 
To compare the effect of atheroprotective and 
atheroprone waveforms on responsiveness to 
statins, EC were exposed to LSS (12 dynes/cm2) 
or oscillatory flow (OF) (±5 dynes/cm2 at 1Hz) 
(21). A 10-fold increase in HO-1 expression was 
seen in EC exposed to 24h LSS, while HO-1 
mRNA induction was reduced to 3-fold in EC 
exposed to OF. Furthermore, OF-conditioned EC 
failed to demonstrate a synergistic relationship 
with atorvastatin (Figure 2F).  
 
LSS and atorvastatin induce an enhanced anti-
oxidant effect  
To investigate the functional relevance of HO-1 
induction, EC were exposed to free radical-
induced injury. Atorvastatin (0.6µM) failed to 
protect static-cultured HUVEC exposed to H2O2 
(50µM). However, EC exposed to LSS for 24h 
were protected by 50%, and this was 
significantly enhanced by atorvastatin (0.6µM) 
(Figure 3A). An oxygen radical-sensitive 
fluorescent probe (CM-H2DCFDA) was used to 
explore the ability of atorvastatin to modulate 
oxidative stress. LSS alone led to low-level 
oxidant generation, while exposure of EC to 
H2O2 (5μM) induced a maximal response (Figure 
3B). Pre-treatment of static-cultured EC with 
atorvastatin (0.6μM) failed to protect, whereas 
LSS alone significantly reduced H2O2 generated 
oxidative stress. However, as predicted maximal 
protection was seen in LSS-conditioned EC 
treated with atorvastatin (Figure 3B). Treatment 
with leptin also increased EC oxidant generation 
by 5-fold. LSS was again protective, with 
maximal reduction in leptin-induced oxidative 
stress seen in those cells exposed to both LSS 
and atorvastatin (Figure 3C).  
 
To determine the role of HO-1 in the 
cytoprotective response, HUVEC were 
transfected with HO-1-specific or control siRNA. 
HO-1 siRNA reduced mRNA levels by 80% 
(Supplementary Figure 2A) (18). Interference 
with HO-1 expression significantly reduced 
cytoprotection against H2O2-induced cell death 
afforded by atorvastatin in LSS-conditioned EC, 
from 75% to 40% (Figure 3D), suggesting HO-1 
is an important but not necessarily unique 
protective mechanism. In line with reduced HO-
1 induction, exposure of EC to an atheroprone 
OF pattern revealed markedly attenuated 
protection against H2O2. Moreover, atorvastatin 
failed to enhance cytoprotection against oxidant 
injury in this setting (Figure 3E). 
 
LSS and atorvastatin in combination reduce 
intracellular cholesterol 
As shown in Figure 4A, exposure of HUVEC to 
LSS, or treatment of static-cultured EC with 
atorvastatin (0.6µM), resulted in a modest 
reduction in intracellular cholesterol, which did not 
reach significance. However, consistent with the 
effect on HO-1 expression, pre-conditioning of 
EC with LSS prior to addition of atorvastatin 
resulted in a significant fall in intracellular 
cholesterol of up to 60%. These data, combined 
with that in Figure 2, suggests that EC exposure 
to LSS significantly enhances responsiveness to 
statins.     
 
LSS and atorvastatin stabilize HO-1 mRNA 
To determine whether LSS and atorvastatin 
regulate HO-1 expression post-transcriptionally, 
EC were exposed to LSS in the presence or 
absence of atorvastatin, prior to addition of 
actinomycin D (2 μg/ml) and analysis of HO-1 
by qRT-PCR. Treatment with actinomycin D 
resulted in less than 5% cell death as estimated 
by trypan blue exclusion studies. The rapid decay 
of HO-1 mRNA in static-cultured EC was not 
delayed by atorvastatin. In contrast, LSS 
increased HO-1 mRNA stability and this delay in 
 6
degradation was further prolonged by 
atorvastatin (Figure 4B).  
 
Inhibition of KLF2 and Nrf2 prevents LSS and 
atorvastatin synergy  
KLF2 is important for LSS-induced vascular 
endothelial cytoprotection (28), and in statin-
mediated induction of HO-1 in static EC (18). 
Thus, we explored the role of KLF2 in flow-
mediated upregulation of HO-1. KLF2-targeted 
siRNA reduced expression in HUVEC by 80% 
(Supplementary Figure 2B) (18). However, 
interference with the KLF2 transcript did not 
alter HO-1 induction by LSS (Figure 5A) (29). 
Likewise, KLF2 depletion did not reduce LSS-
mediated cytoprotection against oxidant-induced 
injury, when compared with control siRNA 
(Figure 5B). 
 
The Nrf2-Keap1 system regulates cytoprotective 
gene expression via the antioxidant responsive 
element (ARE), with several ARE-regulated 
genes induced by LSS (29). A recombinant 
adenovirus expressing a DN-Nrf2 construct 
(MOI 100) demonstrated the importance of Nrf2 
in HO-1 induction by LSS (Figure 5C). The 
functional consequences of HO-1 suppression 
were evident when HUVEC expressing DN-Nrf2 
were exposed to LSS followed by H2O2. DN-
Nrf2 significantly reduced LSS-mediated 
protection against oxidant-induced injury 
(Figure 5D). 
 
The distinct transcription factors used by 
atorvastatin and LSS therefore suggested that 
activation of both was required for maximal 
synergistic induction of HO-1. To investigate 
this, HUVEC were transfected with KLF2 
siRNA and Adv DN-Nrf2. Atorvastatin (0.6µM) 
in the presence of siRNA or adenoviral vectors 
had no effect on HO-1 expression (Figure 5E-F). 
KLF2 siRNA did not affect LSS induction of 
HO-1, while reducing HO-1 expression in EC 
exposed to LSS and atorvastatin by 40% 
(Supplementary Figure 2C). Inhibition of Nrf2 
alone had a more marked effect, reducing HO-1 
expression in LSS and statin-treated EC by 60% 
(Figure 5E). Although co-transfection of EC with 
KLF2 siRNA and DN-Nrf2 significantly 
attenuated LSS-induced HO-1 when compared to 
EC transfected with control siRNA and Adv βgal, 
this was equivalent to that seen with Nrf2-DN 
alone. However, inhibition of both transcription 
factors led to a maximal reduction in LSS and 
atorvastatin-induced HO-1 upregulation, 
reducing this by 80% from 12.5 to 2.5-fold, 
supporting the view that both KLF2 and Nrf2 
activation is required (Figure 5F).    
 
Akt activation regulates LSS and atorvastatin 
synergy 
We next explored PI-3K/Akt activation, which is 
known to occur in EC exposed to LSS or statins 
(30). Atorvastatin (0.6µM) failed to increase Akt 
phosphorylation (Ser473) in static-cultured cells 
(Figure 6A). However, prolonged LSS increased 
Akt phosphorylation and this was further 
enhanced by atorvastatin. The importance of Akt 
was confirmed with Adv-DN-Akt (MOI 100) 
which inhibited LSS-induced HO-1 expression 
and the synergy between LSS and atorvastatin, a 
response not seen with the ßgal control (Figure 
6B). 
 
To investigate the relationship between Akt, 
KLF2 and Nrf2, we analyzed changes in KLF2 
and Nrf2 expression following exposure to LSS 
and atorvastatin. Inhibition of Akt reversed both 
LSS-induced expression of KLF2 and the 
synergistic upregulation in LSS-conditioned EC 
exposed to atorvastatin (Figure 6C).  Likewise, 
the induction of Nrf2 mRNA by LSS, and the 
enhanced response in the presence of atorvastatin, 
was reversed by DN-Akt (Figure 6D), consistent 
with a recent study which reported that flow-
induced translocation of Nrf2 requires PI-3K/Akt 
activation (29). Thus, EC pre-conditioned with 
LSS and treated with atorvastatin exhibit optimal 
Akt phosphorylation, activation of KLF2 and 
Nrf2, resulting in maximal HO-1 expression. 
 
The nitric oxide synthase (NOS) inhibitor L-
NAME was used to investigate eNOS and nitric 
oxide in HO-1 induction, recognizing that PI-3K 
activity, LSS and statins increase eNOS 
expression and phosphorylation. Induction of 
eNOS mRNA was maximal in EC exposed to 
LSS and atorvastatin and this was dependent 
upon activation of Akt (Figure 6E). Although the 
presence of L-NAME did not alter basal HO-1 
expression, NOS inhibition reduced LSS-
mediated HO-1 induction by 50%, and prevented 
the synergy between atorvastatin and LSS 
(Figure 7A). Next we sought to determine the 
effect of L-NAME on the activation of KLF2 and 
Nrf2. To assess KLF2 activation, we analyzed 
expression of its target gene thrombomodulin 
(31). As seen in Figure 7B, LSS induced 
expression of thrombomodulin, a response 
enhanced by atorvastatin. However, the presence 
of L-NAME did not significantly inhibit this 
response. To study Nrf2 activation, EC nuclear 
extracts were isolated and binding of Nrf2 to the 
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antioxidant responsive element quantified using 
a TransAM™ assay. LSS increased Nrf2 
activation by 4-fold, while atorvastatin alone 
(0.6μM) had no effect, nor did it increase 
activation in EC pre-conditioned with LSS. 
Finally, pre-treatment with L-NAME did not 
influence the activation of Nrf2 (Figure 7C). 
Together these data suggest that optimal 
induction of eNOS in response to LSS and 
atorvastatin is a consequence of Nrf2 and KLF2 
activation and in turn contributes to the increase 
in HO-1 expression.   
 
Discussion  
We have explored the hypothesis that LSS 
conditioning of endothelium enhances the 
cytoprotective effects of statins, using HO-1 
induction as a model. Wide-ranging lipid-
independent effects of statins have been reported 
(6). However, the statin concentration used often 
exceeds that measured in the plasma during 
pharmacokinetic studies, raising the question of 
therapeutic relevance. Alternatively, this may 
reflect reduced responsiveness of cultured cells 
to statins and increased hepatic metabolism of 
these drugs in rodents. Detection of HO-1 protein 
upregulation by statins in endothelium has varied, 
reflecting differences in the EC type studied and 
the source of statin (14-16,18,32).  
Notwithstanding, we now show that LSS pre-
conditioning of vascular EC significantly reduces 
the atorvastatin concentration required to induce 
maximal HO-1 induction in vitro, with LSS and 
atorvastatin exhibiting synergy. Moreover, using 
en face confocal microscopy we have 
demonstrated, to the best of our knowledge for 
the first time, statin-mediated induction of HO-1 
in the aortic endothelium in vivo, which was 
optimal at an atheroprotected site predicted to be 
exposed to LSS. This study therefore proves the 
principle that biomechanical signalling makes a 
significant contribution to endothelial 
responsiveness to pharmacological agents and 
specifically suggests that EC at atherosusceptible 
regions of vessels may fail to be maximally 
affected by statins. 
 
Atherosclerosis is a geometrically focal disease, 
predominantly located at arterial branch points 
and curvatures where the vascular endothelium is 
exposed to disturbed flow, characterized by a 
high oscillatory shear index and low time-
averaged shear stress amplitude (19,33). In 
contrast, unidirectional LSS is an essential 
component of vascular endothelial homeostasis. 
The atheroprotective waveform is anti-
inflammatory, anti-apoptotic and anti-oxidant 
(34-36). Additional transcriptional responses to 
biomechanical forces, including those mediated 
by KLF2 and Nrf2, are important for 
atheroprotection. KLF2 is induced in 
endothelium exposed to LSS and is an important 
regulator of eNOS and thrombomodulin, exerting 
anti-inflammatory and anti-thrombotic effects 
(28,37,38). Nrf2 activity is central to LSS-
mediated regulation of anti-oxidant genes 
including HMOX1, THIOREDOXIN 
REDUCTASE1 and GLUTATHIONE 
REDUCTASE (29,39). 
 
Pre-conditioning HUVEC with unidirectional 
LSS increased responsiveness to statins so that 
atorvastatin (0.6µM), which failed to upregulate 
HO-1 in static-cultured EC, induced a maximal 
increase in the HMOX1 transcript. In contrast, 
exposure to OF, representing the atheroprone 
waveform, revealed significant attenuation in 
shear stress-induced HO-1 expression, and no 
response to atorvastatin. Although exposure to 
LSS reduced the concentration of statin required 
to induce HO-1, we failed to demonstrate 
induction with atorvastatin 0.3µM, which is 
thought to be at the upper limit of the plasma 
concentration achieved therapeutically (40). This 
may reflect the lack of pulsatility in the LSS 
model, which is a limitation of our study. 
Available data suggest that KLF2 expression and 
Nrf2 translocation are maximal in response to 
pulsatile unidirectional LSS (29,41), and we 
speculate that this would further reduce the statin 
concentration required to induce optimal HO-1 
expression.  
 
The functional importance of LSS and 
atorvastatin synergy was confirmed by increased 
resistance of EC to the oxidative stress induced 
by leptin, and protection against H2O2-induced 
EC death. The additional protective effect seen in 
EC exposed to both LSS and atorvastatin was 
lost in EC pre-treated with HO-1 siRNA. 
However, HO-1 depletion did not completely 
inhibit cytoprotection, suggesting other anti-
oxidant genes induced by LSS including 
NAD(P)H:QUININE OXIDOREDUCTASE1, 
NAD(P)H OXIDASE, SUPEROXIDE 
DISMUTASE, THIOREDOXIN REDUCTASE1 
and GLUTATHIONE REDUCTASE may be 
involved (29). The failure of atorvastatin to 
increase HO-1 in EC exposed to OF rendered the 
cells susceptible to oxidant-induced injury, 
reflecting also the failure of OF to induce the 
anti-oxidant genes above (29). The mechanisms 
through which HO-1 products exert anti-oxidant 
actions remain to be fully determined. Of note 
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activation of STAT3 is important for the 
protective effects of HO-1 and CO against 
hyperoxia-induced murine lung injury (42). 
However, while STAT3 merits further 
investigation as a downstream mediator of 
LSS+atorvastatin-induced HO-1, it has been 
reported that both statins (43,44) and shear stress  
(45) may inhibit STAT3 activation.  
  
Analysis of total EC cholesterol emphasized the 
increased efficacy of atorvastatin in cells pre-
conditioned by LSS. A significant fall in 
cholesterol was only seen in EC exposed to both 
LSS and atorvastatin. Depletion of membrane 
cholesterol results in increased aortic EC 
membrane stiffness via effects on F-actin (46), 
and may alter LSS-induced intracellular 
signaling (47). Moreover, inhibition of 
cholesterol synthesis by statins may reduce 
caveolin-1 expression through changes in sterol 
regulatory element activity. This reduces 
caveolin-1-mediated inhibition of eNOS activity 
(48,49), and hence may play a role in the HO-1 
induction observed herein. In contrast, 
cyclosporin A reduced EC cholesterol and 
inhibited eNOS phosphorylation {Lungu, 2004 
#5084). Thus, further studies are required to 
investigate the specific effect and consequences 
of statin-mediated reduction in EC cholesterol, 
and to identify mechanisms through which EC 
are rendered more responsive to statins by LSS.  
 
KLF2 and Nrf2 activity is increased in EC in 
response to LSS, with distinct downstream 
effects (29,38,50). KLF2 expression was induced 
by 24h LSS, although as reported (29) siRNA 
depletion of KLF2 had no effect on HO-1 
induction. In contrast, expression of DN-Nrf2 
significantly reduced HO-1 upregulation by LSS. 
Moreover, combined inhibition of KLF2 and 
Nrf2 was required to reverse the synergistic 
induction of HO-1. These data suggest KLF2 and 
Nrf2 have distinct, complementary actions and 
together act to maximally enhance vascular 
cytoprotection against oxidative stress. This 
concept is supported by a study demonstrating 
that KLF2 enhances the antioxidant activity of 
Nrf2 (50). We propose that statins, through their 
ability to increase KLF2 expression, 
therapeutically manipulate this interaction 
leading to optimal LSS-induced activation of 
Nrf2. 
 
LSS-induced PI-3K/Akt signalling, although 
maximal after 1-2h, may be prolonged and 
sufficient for Nrf2 activation following 24h of 
atheroprotective flow (51,52). Thus, PI-3K 
antagonist LY290042 inhibited the LSS-induced 
Nrf2-dependent reduction in intracellular redox 
levels (29). In our model prolonged LSS 
increased Akt phosphorylation, a response 
significantly enhanced by atorvastatin. 
Furthermore, LSS induction of HO-1 and 
synergy with atorvastatin, was inhibited by DN-
Akt. Likewise, inhibition of Akt attenuated 
increases in KLF2, Nrf2 and eNOS mRNA 
following exposure to LSS and atorvastatin.  
 
Although HO-1 induction by LSS was 
significantly reduced by L-NAME, expression 
remained above that in static cells. However, 
synergistic induction of HO-1 by LSS and 
atorvastatin was completely inhibited by L-
NAME. In contrast inclusion of L-NAME failed 
to inhibit LSS+atorvastatin-mediated induction 
of KLF2 and Nrf2, suggesting NO is acting 
downstream of these transcription factors. 
HMOX1 induction is typically transcriptional and 
independent of changes in mRNA stability (7). 
Notwithstanding, exposure to LSS delayed HO-1 
mRNA degradation, a response enhanced by 
atorvastatin. Moreover, NO may act to stabilize 
HO-1 mRNA (53) and is a likely regulator of the 
post-transcriptional effect observed. Thus, we 
propose that exposure of LSS-conditioned 
vascular endothelium to atorvastatin results in 
sustained Akt phosphorylation, KLF2 and Nrf2 
activation, increased eNOS activity and both 
transcriptional and post-transcriptional events 
leading to optimal HO-1 induction and resistance 
to oxidative stress.  
 
The cytoprotective effects of statins in vascular 
endothelium are increasingly recognized, 
although questions remain regarding their 
clinical relevance. Our data suggest that LSS 
enhances endothelial responsiveness to statins 
and that HO-1 induction represents an important 
component of the vasculoprotective profile of 
these drugs. Importantly, we also demonstrate an 
attenuated response in EC exposed to an 
atheroprone waveform, suggesting that 
protection from statins may be sub-optimal at 
sites most susceptible to atherosclerosis. This 
observation may have important implications for 
the efficacy of statins in patients with coronary 
artery disease, and for their increasing use in 
prevention of accelerated atherosclerosis in 
patients with systemic inflammatory diseases. 
The data emphasize the need for novel therapies, 
such as those targeting KLF2 or Nrf2, to 
optimize vasculoprotection.  
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2The abbreviations used are: LDL, low-density lipoprotein;; HO-1, heme oxygenase-1; CO, carbon 
monoxide; VSMC, vascular smooth muscle cells; EC, endothelial cells; LSS, laminar shear stress; NO, 
nitric oxide; eNOS, endothelial nitric oxide synthase; KLF2, Kruppel-like Factor2; Nrf2, NF-E2-related 
factor-2; H2O2, hydrogen peroxide; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide; PI-3K, phosphoinositide-3 kinase; L-NAME, NG-nitro-L-arginine methyl ester; HUVEC, 
human umbilical vein endothelial cells; HAEC, human aortic endothelial cells; FBS, fetal bovine serum; 
OF, oscillatory flow; DN, dominant-negative; H2DCF, dihydrodichlorofluorescein; SEM, standard error 
of the mean; MOI, multiplicity of infection; NADP, nicotinamide adenine dinucleotide phosphat; 
STAT3, signal transducer and activator of transcription 3. 
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Figure Legends 
 
Figure 1: Atorvastatin induces endothelial HO-1 expression in murine aortic EC 
HO-1 expression in murine aortic endothelium of C57BL/6 mice assessed en face using anti-HO-1 
(red). EC were identified by FITC-conjugated anti-CD31 (green) and cell nuclei with Draq5 (purple). 
An isotype-matched control antibody did not bind (not shown). A, B. Representative images of HO-1 
staining from (A) the greater curvature (low probability (LP) area), and (B) the lesser curvature (high 
probability (HP) area). C. HO-1 expression was quantified (mean ± SD) by image analysis of 
fluorescence intensity in multiple cells at 3 distinct sites and expressed as EC fluorescence above a 
threshold intensity defined by background fluorescence. *p<0.05.  
 
Figure 2: LSS and statins synergistically enhance HO-1 expression. HUVEC were exposed to 
static conditions (grey bars) or unidirectional LSS (12 dynes/cm2) (black bars) for 24h. After 12h, 
statin or vehicle was added to the culture medium. A. atorvastatin (AT) 2.5µM, B. AT 0.6µM, Dotted 
lines represent predicted HO-1 mRNA level achieved by an additive response between LSS and 
atorvastatin.  C. Dose response for AT, # = synergistic response, § = additive response, with HO-1 
RNA quantified by real-time PCR. Dotted line represents HO-1 mRNA induced by LSS alone. D. 
HUVEC were transfected with pHO-1 luciferase reporter construct or pGL3-basic, prior to exposure to 
static conditions or unidirectional LSS and addition of AT 0.6µM or vehicle as above and analysis of 
luciferase activity at 24h. E. HUVEC were exposed to static culture or LSS for 24h with atorvastatin 
added after 12h and HO-1 analyzed by immunoblotting. F. HUVEC were exposed to static conditions 
(grey bars), LSS (12 dynes/cm2) (black bars) or oscillatory flow (OF) (1Hz, +/-5 dynes/cm2) (hatched 
bars) for 24h. After 12h, statin or vehicle was added to the culture medium. Data are expressed as 
mean ± SEM from 3 experiments, *p<0.05, **p<0.01.  
 
Figure 3: LSS and statins synergistically enhance resistance to oxidative stress.  HUVEC were 
exposed to static conditions (grey bars) or LSS (12 dynes/cm2) (black bars) for 24h. After 12h, statin 
or vehicle was added to the culture medium. A. HUVEC were treated with H2O2 (50 μM) or vehicle for 
45 min. Live cells were quantified by trypan blue exclusion, expressed as a percentage of untreated 
control (n=3). B and C. Cells were treated as in A, followed by loading with CM-H2DCFDA (5μM) and 
exposure to B. H2O2 (5μM) for 30 min or C. leptin (100 ng/ml) for 120 mins. Oxidative stress was 
quantified by flow-cytometric analysis (n=3). D. HUVEC were left untreated or transfected with 
scrambled siRNA (CT) or HO-1 siRNA for 24h, prior to exposure to LSS and atorvastatin (0.6µM) for 
24h as in A. EC were treated with H2O2 (50 μM) as above and live cells quantified by MTT assay 
(percent untreated control, n=4). E. HUVEC were exposed to static conditions (grey bars) or 
oscillatory flow (OF) (1Hz, +/-5 dynes/cm2) (hatched bars) for 24h. After 12h, atorvastatin (0.6µM) 
(AT) or vehicle were added to the culture medium. After exposure to H2O2  live cells were quantified by 
MTT assay. Data expressed as mean ± SEM from 3 experiments. *p<0.05, **p<0.01.   
 
Figure 4: Statin and LSS reduce cholesterol and enhance HO-1 mRNA stability. HUVEC were 
exposed to static conditions or LSS (12 dynes/cm2) for 24h. After 12h, atorvastatin (0.6μM) or vehicle 
was added to the culture medium. A. EC were homogenized and cholesterol content was analyzed by 
mass spectrometry and expressed as μg/106 cells.  B. HUVEC monolayers were divided into sections 
using a water-resistant pen and actinomycin D (2 μg/ml) or vehicle added. EC were harvested after 0-
6h for RNA extraction. HO-1 mRNA was quantified by qRT-PCR, plotted as a percentage of mRNA 
expression prior to the addition of actinomycin D. Data are presented as mean ± SEM (n=3), *p<0.05. 
 
Figure 5: Synergistic HO-1 induction by LSS requires KLF2 and Nrf2. A and B. HUVEC were 
left untransfected (UT) or transfected with scrambled siRNA (CT) or KLF2 siRNA, prior to exposure 
to static conditions or LSS (12 dynes/cm2) for 24h. After 12h, atorvastatin (0.6μM) or vehicle was 
added to the culture medium. A. HO-1 mRNA was quantified by real-time PCR, a representative 
cDNA gel of PCR products is shown. B. Following exposure to atorvastatin and LSS, HUVEC were 
treated with H2O2 (50 μM) or vehicle for 45 min. Live cells were quantified by MTT assay (percent 
untreated control, n=4). C and D. HUVEC were left untransfected (UT) or transfected with an 
adenovirus expressing β galactosidase (βgal) or DN-Nrf2 prior to exposure to static conditions or LSS 
(12 dynes/cm2) for 24h. C. HO-1 mRNA was quantified by real-time PCR. D. HUVEC were treated 
with H2O2 (50 μM) or vehicle for 45 min and live cells quantified by MTT assay. E and F. HUVEC were 
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left untransfected (UT) or transfected with E. βgal or DN-Nrf2 adenovirus or F. control siRNA (CT), 
KLF2 siRNA, βgal control or DN-Nrf2 adenovirus prior to exposure to static conditions (grey bars) or 
LSS (black bars) for 24h with addition of vehicle or atorvastatin (0.6μM) after 12h. HO-1 mRNA was 
quantified by real-time PCR. Data are expressed as mean ± SEM from 3 experiments *p<0.05, 
**p<0.01. 
 
Figure 6: Synergistic induction of HO-1 is dependent upon Akt.  HUVEC were exposed to static 
conditions (grey bars) or unidirectional LSS (12 dynes/cm2) (black bars) for 24h. After 12h, 
atorvastatin (0.6µM) (AT) or vehicle control was added. A. EC were immunoblotted with Abs against 
phosphorylated-Akt (Ser473) and α-tubulin. The histogram shows phospho-Akt expression quantified 
by densitometry relative to the α-tubulin bands. B-E. HUVEC were left untransfected (UT) or 
transfected with a βgal control adenovirus (βgal) or DN-Akt adenovirus prior to exposure to static 
conditions or LSS (12 dynes/cm2) for 24h as above. HO-1 (B), KLF2 (C), Nrf2 (D) and eNOS (E) 
mRNA levels were quantified by real-time PCR. Data are expressed as mean ± SEM from 3 
experiments *p<0.05, **p<0.01. 
 
Figure 7: Synergistic induction of HO-1 is dependent upon activity of eNOS. HUVEC were pre-
treated with L-NAME (L-N) (1mM) or vehicle prior to exposure to static conditions or unidirectional 
LSS (12 dynes/cm2) for 24h with atorvastatin (0.6µM) (AT) or vehicle control added after 12h. A. 
HO-1 and B. thrombomodulin (TM) mRNA levels were analyzed by real-time PCR, or C. Nrf2 
activation was assessed in EC nuclear extracts by analysis of Nrf2 binding to the antioxidant 
responsive element, quantified using a TransAM™ assay. Data are expressed as mean ± SEM from 2-
3 experiments *p<0.05, **p<0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
